Publications by authors named "Ching-Wei David Tzeng"
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol
March 2022
Article Synopsis
- Hepatocellular carcinoma (HCC) has high recurrence rates after surgery, and there are currently no approved standard therapies for pre- or post-surgery treatment, prompting the exploration of immunotherapy options.
- A phase 2 trial involved assigning patients with resectable HCC to receive either nivolumab alone or in combination with ipilimumab, assessing safety, tolerability, and secondary outcomes like overall response and progression-free survival.
- The trial enrolled 30 patients, finding that adverse events were more common in the combination treatment group (43%) compared to nivolumab alone (23%), with liver enzyme increases being the most reported side effect.
Objectives: This study investigated the impact of neoadjuvant radiation therapy (XRT) on postoperative outcomes following pancreaticoduodenectomy for pancreatic cancer.
Methods: The American College of Surgeons National Quality Improvement Program database was queried for the period 2005-2010 to assess complication rates following pancreaticoduodenectomy for pancreatic cancer. Two groups of patients were identified, comprising those who received neoadjuvant XRT and those who did not (control group).
Background: In treating pancreatic cancer, there is no clearly defined optimal sequence of chemotherapy, radiation therapy and surgery. Therefore, cost-effectiveness should be considered. The objective of this study was to compare cost and outcomes between a surgery-first approach versus neoadjuvant chemoradiation followed by surgery for resectable pancreatic head cancer.
View Article and Find Full Text PDF